Skip to main content
. 2012 Oct 9;81(1):15–42. doi: 10.3797/scipharm.1208-13

Fig. 2.

Fig. 2

a: Interaction of Gefitinib with the binding site of EGFR; b: Interaction of compound 6.2 with the binding site of EGFR. H-bonds are shown as black lines.